We are focused on understanding how inflammation and fibrosis contribute to diseases of the heart and developing therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.


From Healthy to Heart Condition: A Mother's Account of Her Son's Myocarditis Battle

From Healthy to Heart Condition: A Mother's Account of Her Son's Myocarditis Battle

Nicole Janes, the mother of 14-year-old Cruze Janes, shares their story of the profound impact of his myocarditis diagnosis: “It started on a Sunday and by Friday he needed to be admitted to the hospital for decreased cardiac function.”

Read More
Finding the Strength to Persevere: A 5-Year Struggle with Chronic Myopericarditis

Finding the Strength to Persevere: A 5-Year Struggle with Chronic Myopericarditis

Five years ago, Newell Rand, aged 23, was diagnosed with chronic myopericarditis after a series of incorrect diagnoses: “The biggest motivation for me is being able to inspire others.”

Read More
Young Athlete Survives Viral Myocarditis

Young Athlete Survives Viral Myocarditis

Jorge Estevez, 27, lived an active lifestyle as a competitive runner before being diagnosed with viral myocarditis: “My only hope for the future is not just to survive, but to get back to the old me.”

Read More
Load More

Community Engagement

Myocarditis Foundation logo

Myocarditis Foundation

The Myocarditis Foundation is a voluntary, non-profit organization that is dedicated to providing information about myocarditis to medical professionals, patients and their families, with the goal of saving more lives.

Learn More
Pericarditis Alliance logo

Pericarditis Alliance

The Pericarditis Alliance is a nonprofit organization dedicated to the diagnosis, management, and treatment of pericardial disease through research, education, and support for patients and healthcare providers.

Learn More


Heart Disease, Pericarditis, Myocarditis and Heart Failure

Conditions affecting the heart are often life-threatening and debilitating. The publications below provide an overview of the impact of pericarditis, myocarditis, and heart failure on patients and healthcare, and include clinical guidelines which describe the causes, symptoms, diagnosis, and management of these diseases.


Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

by Tsao CW, Aday AW, Almarzooq ZI, et al. Circulation. 2023;147(8):e93-e621.
View Online


by Basso C. Myocarditis. N Engl J Med. 2022;387(16):1488-1500.
View Online

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

by Heidenreich PA, Bozkurt B, Aguilar D, et al. Circulation. 2022;145(18):e895-e1032.
View Online

Burden of Heart Failure and Underlying Causes in 195 Countries and Territories from 1990 to 2017

by Bragazzi NL, Zhong W, Shu J, et al. Eur J Prev Cardiol. 2021;28(15):1682-1690.
View Online

2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

by McDonagh TA, Metra M, Adamo M, et al. Eur Heart J. 2021;42(36):3599-3726.
View Online

Myocarditis and Inflammatory Cardiomyopathy: Current Evidence and Future Directions

by Tschöpe C, Ammirati E, Bozkurt B, et al. Nat Rev Cardiol. 2021;18(3):169-193.
View Online

Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review

by Chiabrando JG, Bonaventura A, Vecchié A, et al. J Am Coll Cardiol. 2020;75(1):76-92.
View Online

2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases

by Adler Y, Charron P, Imazio M, et al. Eur Heart J. 2015;36(42):2921-2964.
View Online

Inflammation, the Inflammasome, and Fibrosis in Cardiovascular Diseases

Aberrant activation of inflammatory pathways plays a role in many cardiovascular diseases which lead to the inflammation and fibrotic responses that are associated with contributing to the pathogenesis and progression of heart diseases.  The papers below provide a summary of how these pathways and mechanisms contribute to pericarditis, myocarditis, and heart failure, and offer insight into their potential as therapeutic targets.


Emerging Roles of Inflammasomes in Cardiovascular Diseases

by Liao Y, Liu K, Zhu L. Emerging Roles of Inflammasomes in Cardiovascular Diseases. Front Immunol. 2022;13:834289.
View Online

The Inflammasome as a Therapeutic Target for Myopericardial Diseases

by Imazio M, Abbate A. Minerva Cardiol Angiol. 2022;70(2):238-247.
View Online

Targeting the Inflammasome in Cardiovascular Disease

by Olsen MB, Gregersen I, Sandanger Ø, et al. JACC Basic Transl Sci. 2021;7(1):84-98.
View Online

Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

by Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, et al. Front Physiol. 2021;12:746494.
View Online

The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches

by Mauro AG, Bonaventura A, Vecchié A, et al. JACC Basic Transl Sci. 2021;6(2):137-150.
View Online

Inflammation in Heart Failure: JACC State-of-the-Art Review

by Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. J Am Coll Cardiol. 2020;75(11):1324-1340.
View Online

Cannabidiol: Mechanisms and Effects

Cannabidiol has been shown to demonstrate anti-inflammatory and anti-fibrotic effects, including attenuating multiple inflammatory signaling pathways known to play an important role in pericarditis, myocarditis, and heart failure. An overview of cannabidiol’s effects on these cellular targets are described below.


Cannabidiol inhibits the mesothelial to mesenchymal transition in experimental pericarditis

by Martinez Naya N et al. 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases: Poster Viewing Sessions
View Online

Cannabidiol As A Potential Treatment For Heart Failure With Preserved Ejection Fraction

by Lozano O et al. Heart Failure Society of America Annual Scientific Meeting 2023: ePoster Viewing Session III.
View Online

Molecular and Cellular Mechanisms of Action of Cannabidiol

by Martinez Naya N, Kelly J, Corna G, et al. Molecules. 2023;28(16):5980.
View Online

Cannabidiol Inhibits Endothelial-to-mesenchymal Transition and also Promotes the Reverse Process in vitro

by Krishnamoorthi MK, Youker KA, Bhimaraj A. Annual Scientific Meeting of the Heart Failure Society of America 2022: Basic and Translational Science Posters.
View Online

Cardioprotective Effect of Cannabidiol in a Non-Ischemic Model of Heart Failure

by Lozano O, García-Rivas G, Ramos M, et al. J Am Coll Cardiol. 2020 Mar, 75 (11_Supplement_1) 705.
View Online

Protective Effects of Pharmaceutically Manufactured Cannabidiol in a Mouse Model of Acute Pericarditis

by Martinez-Naya N, Nirar AH, Kim MM et al. American Heart Association Scientific Sessions 2022: Late-Breaking Basic Science Posters (LBP24).
View Online

Cannabidiol as a Novel Therapeutic for Immune Modulation

by Peyravian N, Deo S, Daunert S, Jimenez JJ. Immunotargets Ther. 2020;9:131-140.
View Online

Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation

by Lee WS, Erdelyi K, Matyas C, et al. Mol Med. 2016;22:136-146.
View Online

Is the Cardiovascular System a Therapeutic Target for Cannabidiol?

by Stanley CP, Hind WH, O'Sullivan SE. Br J Clin Pharmacol. 2013;75(2):313-322.
View Online

Cannabidiol attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy

by Rajesh M, Mukhopadhyay P, Bátkai S, et al. J Am Coll Cardiol. 2010;56(25):2115-2125.
View Online